28463669|t|Pancreatic Cystic Lesions: Diagnostic, Management and Indications for Operation. Part I
28463669|a|We notice an increasing frequency in the detection and evaluation of pancreatic cystic lesions (PCLs) over the last three decades. They show awide spectrum of imaging and clinical features. The diagnosis and discrimination of these lesions are very important because of the risk for concurrent or later development of malignancy. The main reason is the increased awareness of these lesions and the extensive use of cross-sectional imaging, an always improving technique (1). Commonly, PCLs are diagnosed incidentally during investigation for often unrelated and nonspecific abdominal complaints using state-of-the art abdominal imaging (CT, MRT). The term PCN denotes a histologically heterogeneous collection of neoplasms showing a wide spectrum of diagnoses, ranging from completely benign to potentially malignant, to carcinoma in situ, to frankly invasive and malignant (2,3). In 1978, Compagno and Oertel were the first to recognize the crucial distinction between the serous and the mucinous cystic neoplasms of the pancreas by explaining the importance of identifying the mucinous neoplasms because of their overt or latent malignant potential (4,5). Since then, the interest in PCLs increased markedly, especially so with the recognition of the importance and prevalence of intraductal papillary mucinous neoplasms (IPMNs). Nowadays, PCLs represent a common and often difficult challenge in clinical practice, because of the increase in their detection in asymptomatic patients and our still immature understanding of some aspects of their biologic behavior. Their important differences regarding their outcome and the fact of being increasingly often identified has put a special focus on these neoplasms by surgeons, pathologists, gastroenterologists, radiologists, and oncologists alike. Management of patients with PCNs can be challenging and varies considerably among the various subtypes of PCNs. Their treatment ranges from resection of malignant lesions, to resection and/or surveillance in the case of premalignant lesions, to simple observation in the case of benign or indolent lesions. Under these circumstances, the accurate classification of PCNs becomes crucial. Therapeutic decision making and classification rely mainly on the presenting symptoms and radiologic findings, often without actual histologic tissue. It is of extreme importance to identify suspicious features indicating potential or certain malignancy in order to select the appropriate treatment. The risk of overtreatment (unnecessary pancreatectomy) should he balanced carefully with the risk of under treatment (missing the opportunity to cure a potentially curable malignant or premalignant disease).
28463669	0	10	Pancreatic	T023	C0030274
28463669	11	25	Cystic Lesions	T033	C1511606
28463669	27	37	Diagnostic	T033	C0011900
28463669	39	49	Management	T058	C0376636
28463669	54	65	Indications	T078	C3146298
28463669	70	79	Operation	T061	C0543467
28463669	101	111	increasing	T169	C0442808
28463669	112	121	frequency	T081	C1705502
28463669	129	138	detection	T061	C1511790
28463669	143	153	evaluation	T058	C0220825
28463669	157	167	pancreatic	T023	C0030274
28463669	168	182	cystic lesions	T033	C1511606
28463669	184	188	PCLs	T033	C1511606
28463669	210	217	decades	T081	C2981279
28463669	235	243	spectrum	T077	C2827424
28463669	247	254	imaging	T060	C0011923
28463669	259	267	clinical	T080	C0205210
28463669	268	276	features	T080	C2348519
28463669	282	291	diagnosis	T033	C0011900
28463669	296	310	discrimination	T169	C2945687
28463669	320	327	lesions	T033	C1511606
28463669	362	366	risk	T078	C0035647
28463669	371	381	concurrent	T079	C0205420
28463669	391	402	development	T169	C1527148
28463669	406	416	malignancy	T191	C4282132
28463669	441	450	increased	T081	C0205217
28463669	451	460	awareness	T041	C0004448
28463669	470	477	lesions	T033	C1511606
28463669	486	495	extensive	T080	C0205231
28463669	503	526	cross-sectional imaging	T170	C3824793
28463669	548	557	technique	T169	C0449851
28463669	573	577	PCLs	T033	C1511606
28463669	582	591	diagnosed	T033	C0011900
28463669	592	604	incidentally	T169	C0444507
28463669	612	625	investigation	T058	C0220825
28463669	636	645	unrelated	T033	C0445356
28463669	650	661	nonspecific	T078	C0750540
28463669	662	671	abdominal	T029	C0000726
28463669	672	682	complaints	T184	C1660601
28463669	706	715	abdominal	T029	C0000726
28463669	716	723	imaging	T060	C0011923
28463669	725	727	CT	T060	C0040405
28463669	729	732	MRT	T060	C0024485
28463669	744	747	PCN	T191	C1333190
28463669	758	772	histologically	T169	C0205462
28463669	773	786	heterogeneous	T080	C0019409
28463669	801	810	neoplasms	T191	C0027651
28463669	826	834	spectrum	T077	C2827424
28463669	838	847	diagnoses	T033	C0011900
28463669	849	856	ranging	T081	C1514721
28463669	873	879	benign	T080	C0205183
28463669	883	894	potentially	T080	C3245505
28463669	895	904	malignant	T080	C0205282
28463669	909	918	carcinoma	T191	C0007097
28463669	919	926	in situ	T082	C0444498
28463669	939	947	invasive	T080	C0205281
28463669	952	961	malignant	T080	C0205282
28463669	1016	1025	recognize	T080	C0205396
28463669	1030	1037	crucial	T080	C1511545
28463669	1038	1049	distinction	T080	C1705242
28463669	1062	1102	serous and the mucinous cystic neoplasms	T191	C0476127
28463669	1110	1118	pancreas	T023	C0030274
28463669	1151	1162	identifying	T041	C0020792
28463669	1167	1185	mucinous neoplasms	T191	C1334811
28463669	1203	1208	overt	T169	C1513040
28463669	1212	1218	latent	T080	C0205275
28463669	1219	1228	malignant	T080	C0205282
28463669	1229	1238	potential	T080	C3245505
28463669	1274	1278	PCLs	T033	C1511606
28463669	1279	1288	increased	T081	C0205217
28463669	1289	1297	markedly	T080	C0522501
28463669	1322	1333	recognition	T080	C0205396
28463669	1356	1366	prevalence	T081	C0220900
28463669	1370	1410	intraductal papillary mucinous neoplasms	T191	C3160815
28463669	1412	1417	IPMNs	T191	C3160815
28463669	1430	1434	PCLs	T033	C1511606
28463669	1487	1504	clinical practice	T061	C0695275
28463669	1521	1529	increase	T169	C0442805
28463669	1539	1548	detection	T061	C1511790
28463669	1552	1564	asymptomatic	T033	C0231221
28463669	1565	1573	patients	T101	C0030705
28463669	1588	1596	immature	T080	C0205252
28463669	1597	1610	understanding	T041	C0162340
28463669	1636	1644	biologic	T080	C0205460
28463669	1645	1653	behavior	T053	C0004927
28463669	1699	1706	outcome	T169	C1274040
28463669	1792	1801	neoplasms	T191	C0027651
28463669	1805	1813	surgeons	T097	C0582175
28463669	1815	1827	pathologists	T097	C0334866
28463669	1829	1848	gastroenterologists	T097	C0259901
28463669	1850	1862	radiologists	T097	C0260194
28463669	1868	1879	oncologists	T097	C0259990
28463669	1887	1897	Management	T058	C0376636
28463669	1901	1909	patients	T101	C0030705
28463669	1915	1919	PCNs	T191	C1333190
28463669	1927	1938	challenging	T058	C0805586
28463669	1981	1989	subtypes	T185	C0449560
28463669	1993	1997	PCNs	T191	C1333190
28463669	2005	2014	treatment	T061	C0087111
28463669	2015	2021	ranges	T081	C1514721
28463669	2027	2036	resection	T061	C0728940
28463669	2040	2049	malignant	T080	C0205282
28463669	2050	2057	lesions	T033	C1511606
28463669	2062	2071	resection	T061	C0728940
28463669	2079	2091	surveillance	T058	C0733511
28463669	2099	2103	case	T169	C0868928
28463669	2107	2127	premalignant lesions	T191	C0850639
28463669	2139	2150	observation	T062	C0302523
28463669	2158	2162	case	T169	C0868928
28463669	2166	2172	benign	T080	C0205183
28463669	2176	2184	indolent	T169	C0234227
28463669	2185	2192	lesions	T033	C1511606
28463669	2234	2248	classification	T185	C0008902
28463669	2252	2256	PCNs	T191	C1333190
28463669	2265	2272	crucial	T080	C1511545
28463669	2274	2285	Therapeutic	T169	C0302350
28463669	2286	2301	decision making	T055	C0518155
28463669	2306	2320	classification	T185	C0008902
28463669	2351	2359	symptoms	T184	C1457887
28463669	2364	2383	radiologic findings	T033	C1290916
28463669	2399	2405	actual	T080	C0237400
28463669	2406	2416	histologic	T169	C0205462
28463669	2406	2416	histologic	T169	C0205462
28463669	2417	2423	tissue	T024	C0040300
28463669	2456	2464	identify	T080	C0205396
28463669	2465	2475	suspicious	T078	C0750493
28463669	2485	2495	indicating	T078	C3146298
28463669	2496	2505	potential	T080	C3245505
28463669	2517	2527	malignancy	T191	C4282132
28463669	2563	2572	treatment	T061	C0087111
28463669	2578	2582	risk	T078	C0035647
28463669	2586	2599	overtreatment	T058	C4046039
28463669	2613	2627	pancreatectomy	T061	C0030279
28463669	2667	2671	risk	T078	C0035647
28463669	2681	2690	treatment	T061	C0087111
28463669	2719	2723	cure	T077	C1880198
28463669	2726	2737	potentially	T080	C3245505
28463669	2738	2745	curable	T077	C1880198
28463669	2746	2755	malignant	T080	C0205282
28463669	2759	2771	premalignant	T080	C1514391
28463669	2772	2779	disease	T047	C0012634